International uniform response criteria for multiple myeloma.
New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow Transplant/International Bone Marrow Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system. Categories for stringent complete response and very good partial response are added. The serum free light-chain assay is included to allow evaluation of patients with oligo-secretory disease. Inconsistencies in prior criteria are clarified making confirmation of response and disease progression easier to perform. Emphasis is placed upon time to event and duration of response as critical end points. The requirements necessary to use overall survival duration as the ultimate end point are discussed. It is anticipated that the International Response Criteria for multiple myeloma will be widely used in future clinical trials of myeloma.
Durie
B G M
BG
Aptium Oncology, Inc., Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA 90048, USA. bdurie@aptiumoncology.com
Harousseau
J-L
JL
Miguel
J S
JS
Bladé
J
J
Barlogie
B
B
Anderson
K
K
Gertz
M
M
Dimopoulos
M
M
Westin
J
J
Sonneveld
P
P
Ludwig
H
H
Gahrton
G
G
Beksac
M
M
Crowley
J
J
Belch
A
A
Boccadaro
M
M
Cavo
M
M
Turesson
I
I
Joshua
D
D
Vesole
D
D
Kyle
R
R
Alexanian
R
R
Tricot
G
G
Attal
M
M
Merlini
G
G
Powles
R
R
Richardson
P
P
Shimizu
K
K
Tosi
P
P
Morgan
G
G
Rajkumar
S V
SV
D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D016019:Survival Analysis; D016896:Treatment Outcome